- Home
- YMAB
as 05-30-2025 4:00pm EST
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 192.4M | IPO Year: | 2018 |
| Target Price: | $17.55 | AVG Volume (30 days): | 226.0K |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.63 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.55 - $16.11 | Next Earning Date: | 05-13-2025 |
| Revenue: | $88,658,000 | Revenue Growth: | 4.92% |
| Revenue Growth (this year): | -4.16% | Revenue Growth (next year): | 16.03% |
Stock Insider Trading Activity of Y-mAbs Therapeutics Inc. (YMAB)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Gad Thomas | YMAB | CHIEF BUSINESS OFFICER | Mar 7 '25 | Sell | $5.23 | 10,810 | $56,536.30 | 202,721 | |
| Rossi Michael J | YMAB | PRESIDENT & CEO | Mar 7 '25 | Sell | $5.20 | 3,917 | $20,368.40 | 137,083 |
Latest Y-mAbs Therapeutics Inc. News
YMAB Breaking Stock News: Dive into YMAB Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Oppenheimer Adjusts Price Target on Y-mAbs Therapeutics to $15 From $20, Maintains Outperform Rating
MT Newswires
3 days ago
Wedbush Lowers Price Target on Y-mAbs Therapeutics to $18 From $21, Maintains Outperform Rating
GlobeNewswire
3 days ago
Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline
Insider Monkey
5 days ago
Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
GlobeNewswire
5 days ago
Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting
Simply Wall St.
16 days ago
Y-mAbs Therapeutics First Quarter 2025 Earnings: Beats Expectations
TipRanks
17 days ago
Morning Movers: UnitedHealth sinks following CEO exit and outlook suspension
MT Newswires
17 days ago
Oppenheimer Adjusts Y-mAbs Therapeutics Price Target to $20 From $21, Maintains Outperform Rating
Compare YMAB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "YMAB Y-mAbs Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.